MKI67 and breast cancer: Although there is continued (and probably justified because of the lack of methodology standardisation) resistance to adopt Ki-67 in the routine practice, some international consensuses such as ESMO and Saint Gallendo support its role in distinguishing between the two intrinsic subtypes of HR+ BC namely luminal A and B [46, 47].